Navigation Links
Arena Pharmaceuticals Announces First Quarter 2008 Financial Results
Date:5/7/2008

SAN DIEGO, May 7 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today reported financial results for the first quarter ended March 31, 2008.

Total revenues in the first quarter of 2008 were $2.6 million, compared to $4.9 million in the first quarter of 2007, and included $2.0 million in revenue under Arena's contract manufacturing agreement with Siegfried Ltd and $0.6 million in patent reimbursements from Arena's collaborations with Merck & Co., Inc. and Ortho-McNeil Pharmaceutical, Inc. Arena reported a net loss allocable to common stockholders in the first quarter of 2008 of $55.0 million, or $0.75 per share, compared to a net loss allocable to common stockholders in the first quarter of 2007 of $32.4 million, or $0.53 per share.

"In the first quarter of 2008, we purchased certain pharmaceutical manufacturing assets from Siegfried and secured Siegfried as a supplier of lorcaserin for our planned NDA submission in 2009 and for the potential partnering and commercialization of the drug candidate. Additionally, lorcaserin passed the month-12 ESMB review of echocardiographic data, APD125, our insomnia drug candidate, entered a Phase 2b trial and APD791, our drug candidate for arterial thrombosis, entered a Phase 1b trial," stated Jack Lief, Arena's President and Chief Executive Officer. "This is a productive start to the year, and we look forward to the results from our ongoing clinical trials and advancing our pipeline of innovative therapeutics."

Research and development expenses totaled $47.6 million in the first quarter of 2008, compared to $35.8 million in the first quarter of 2007. This increase in research and development expenses is primarily attributable to increased clinical development c
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Arena Pharmaceuticals to Present at the Bear Stearns 20th Annual Healthcare Conference
2. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review
3. Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiographic Data Safety Monitoring Board Review
4. Arena Pharmaceuticals Selected to Join New NASDAQ NeuroInsights Neurotech Index
5. Arena Pharmaceuticals to Present at Two Upcoming Investor Conferences
6. Arena Pharmaceuticals to Report Third Quarter 2007 Financial Results and to Host Conference Call and Webcast on Wednesday, October 17, 2007
7. Arena Pharmaceuticals Announces Third Quarter 2007 Financial Results
8. Arena Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Arena Pharmaceuticals Appoints Phillip M. Schneider and Randall E. Woods to Board of Directors
10. Arena Pharmaceuticals Initiates Second and Third Pivotal Trials Evaluating Lorcaserin for the Treatment of Obesity
11. Arena Pharmaceuticals Enters Into Strategic Agreements for the Manufacture of Pharmaceutical Material, Including Lorcaserin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... Calif. , June 19, 2013  Continuing its ... myocardial infarction (MI), Beckman Coulter , Inc. announces ... of its new Access AccuTnI+3 troponin I assay for ... "Clinicians have depended on Beckman Coulter,s ... new AccuTnI+3 assay has the proven performance to continue ...
(Date:6/19/2013)... (PRWEB) June 19, 2013 Today DuPont ... young people to become leaders in the greatest challenge ... billion people in 2050. Borel spoke at the ... Conference in Atlanta, about urgent need for students to ... are local, science-based, sustainable and reached in collaboration with ...
(Date:6/19/2013)... 2013 BioConvergence team members Curtis ... at 2013’s BioLogistics Summit in San Francisco earlier ... Cold Chain IQ and IQPC, addressed the increasingly ... in part, attributed to current trends of globalization, ... these trends is an increase in movement, which ...
(Date:6/19/2013)... June 18, 2013 A new look ... costs and other trends will highlight technical sessions at ... this fall. In its 33rd year, the three-day event ... exhibition of key suppliers, approximately 100 technical presentations and ... the international society for optics and photonics , the ...
Breaking Biology Technology:Beckman Coulter Announces FDA Clearance of New Access AccuTnI+3 Troponin I Assay for the Access 2 Immunoassay System 2Beckman Coulter Announces FDA Clearance of New Access AccuTnI+3 Troponin I Assay for the Access 2 Immunoassay System 3DuPont Leader Calls for New Generation of Food Visionaries to Fight Hunger 2BioConvergence® Presents at BioLogistics Summit on Risk Matrix for Biosamples during Shipment 2‘Big Glass’ and Visions for the Future are on the Program for SPIE Photomask Technology 2‘Big Glass’ and Visions for the Future are on the Program for SPIE Photomask Technology 3
... BRUSSELS, Belgium, October 31 Whether your tastes tend,toward ... groups around the U.S. are gearing up to celebrate ... of diabetes., The International Diabetes Federation (IDF), which ... the existing World Diabetes Day,(November 14) as an official ...
... Stephen Slade, R. Wayne Bowman, William Whitson, James ... Magruder, and Richard Braunstein, attended the recent Alcon ... Wave excimer laser system used for LASIK eye ... and refractive experts are listed in the Trusted ...
... Health Insurers, VIRGINIA BEACH, Va., Oct. 30, 2008 ... one of America,s Best Places to Work,In Healthcare -- ... in a,survey conducted by Modern Healthcare magazine., The ... by Modern,Healthcare, was open to all American hospitals, medical ...
Cached Biology Technology:From Race Cars and Google Doodles to Day Spas and Night Lights: Groups Across the U.S. Prepare to Join World Diabetes Day Celebrations on November 14 2From Race Cars and Google Doodles to Day Spas and Night Lights: Groups Across the U.S. Prepare to Join World Diabetes Day Celebrations on November 14 3From Race Cars and Google Doodles to Day Spas and Night Lights: Groups Across the U.S. Prepare to Join World Diabetes Day Celebrations on November 14 4Top Refractive Eye Surgeons Listed in Trusted LASIK Surgeons Directory Make Solid Showing at Annual Alcon Symposium 2Top Refractive Eye Surgeons Listed in Trusted LASIK Surgeons Directory Make Solid Showing at Annual Alcon Symposium 3Top Refractive Eye Surgeons Listed in Trusted LASIK Surgeons Directory Make Solid Showing at Annual Alcon Symposium 4Top Refractive Eye Surgeons Listed in Trusted LASIK Surgeons Directory Make Solid Showing at Annual Alcon Symposium 5Top Refractive Eye Surgeons Listed in Trusted LASIK Surgeons Directory Make Solid Showing at Annual Alcon Symposium 6Top Refractive Eye Surgeons Listed in Trusted LASIK Surgeons Directory Make Solid Showing at Annual Alcon Symposium 7Top Refractive Eye Surgeons Listed in Trusted LASIK Surgeons Directory Make Solid Showing at Annual Alcon Symposium 8AMERIGROUP Corporation Named One of Best Places to Work in Healthcare 2
(Date:6/19/2013)... University study offers further proof that the divergence of ... years ago was profoundly influenced by mutations to DNA ... off. , The study, published June 9 in ... that regulation of genes must play an important role ... and chimps in the proteins produced by genes. Indeed, ...
(Date:6/19/2013)... 2012, the European Medicines Agency (EMA) approved the ... ever gene therapy for clinical use in the ... developed AAV-LPL S447X for the treatment of a ... (LPLD) which affects approximately one or two out ... life-threatening inflammations of the pancreas. Afflicted individuals carry ...
(Date:6/18/2013)...  Paris Air Show – Marvin Test ... a leading provider of innovative test solutions for ... solutions this week at the Paris Air ... including increasingly complex armament systems with longer lifecycles, ... test solutions that address legacy system obsolescence. Marvin ...
Breaking Biology News(10 mins):New research backs theory that genetic 'switches' play big role in human evolution 2New research backs theory that genetic 'switches' play big role in human evolution 3No danger of cancer through gene therapy virus 2Marvin Test Solutions Demonstrates Next-Generation Armament Test Solutions at Paris Air Show 2Marvin Test Solutions Demonstrates Next-Generation Armament Test Solutions at Paris Air Show 3
... PHILADELPHIA An article published in the Ffall 2010 ... their families and caregivers, details the immense challenges faced by ... for proper treatment and care the homeless. ... associate professor of English at the University of Alabama at ...
... Evolutionary biologists at the University of Toronto (U ... role in determining whether a species opts for sexual ... student Lutz Becks and Professor Aneil Agrawal of the ... that inhabit spatially heterogenous environments habitats characterized by ...
... 14 A recent online poll by Unisys Corporation ... fingerprint biometrics over photo identification, PIN numbers or handwritten ... card or requesting personal information. The results indicate increasing ... and combat identity fraud. Responding to the ...
Cached Biology News:CR Magazine sheds light on the burden of cancer on the streets 2Two-Thirds of Consumers Prefer Credit Card Verification by Fingerprint, According to Unisys Poll 2
... the most comprehensive, cost-effective solution to ... incorporated unprecedented quality into both our ... proven detection chemistries and antibodies that ... protocol. It also includes our competitively ...
Human Cell Line Slides...
... Level 2 Detection System combines the ... bonding principle and Signets unique formulation ... specificity and reliablility. Signet reagents will ... manual and automated protocols. ,Signets USA ...
... Detection System combines the indirect labeling ... and Signets unique formulation of ultra ... reliablility. Signet reagents will achieve excellent ... automated protocols. ,Signets USA Detection reagents ...
Biology Products: